Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C8H9ClN2O2S |
| Molecular Weight | 232.687 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1NC2=C(C=C(Cl)C=C2)S(=O)(=O)N1
InChI
InChIKey=VZRNTCHTJRLTMU-UHFFFAOYSA-N
InChI=1S/C8H9ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-5,10-11H,1H3
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
IDRA-21
Created by
admin on Mon Mar 31 21:00:25 GMT 2025 , Edited by admin on Mon Mar 31 21:00:25 GMT 2025
|
PRIMARY | IDRA-21 is an ampakine drug and a benzothiadiazine derivative. IDRA-21 is a chiral molecule, with (+)-IDRA-21 being the active form. IDRA-21 shows nootropic effects in animal studies, significantly improving learning and memory. It is around 1030 times more potent than aniracetam in reversing cognitive deficits induced by alprazolam or scopolamine,(2)(3) and produces sustained effects lasting for up to 48 hours after a single dose. The mechanism for this action is thought to be through promoting the induction of long-term potentiation between synapses in the brain. IDRA-21 does not produce neurotoxicity under normal conditions, although it may worsen neuronal damage following global ischemia after stroke or seizures. | ||
|
22503-72-6
Created by
admin on Mon Mar 31 21:00:25 GMT 2025 , Edited by admin on Mon Mar 31 21:00:25 GMT 2025
|
PRIMARY | |||
|
689UW7PT68
Created by
admin on Mon Mar 31 21:00:25 GMT 2025 , Edited by admin on Mon Mar 31 21:00:25 GMT 2025
|
PRIMARY | |||
|
IDRA-21
Created by
admin on Mon Mar 31 21:00:25 GMT 2025 , Edited by admin on Mon Mar 31 21:00:25 GMT 2025
|
PRIMARY | IDRA-21 currently has only had animal trials. Dosing in a study with Patas Monkeys was 3 or 5.6 mg/kg p.o. in addition with 30 mg/kg p.o. of Aniracetam. This study indicated that IDRA-21 was 10-fold more potent than Aniracetam at reducing learning defects. A water maze study in rats showed cognitive enhancement at oral dosages of 4-120 mumol/kg. Human dosages have no history of peer-reviewed clinical studies. Some reading online suggested positive human activity at 5-25mg orally. | ||
|
3688
Created by
admin on Mon Mar 31 21:00:25 GMT 2025 , Edited by admin on Mon Mar 31 21:00:25 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
